Novo Nordisk INC. v. Lupin LTD. DO NOT File IN This Case

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Lupin Ltd. (India)
  • Plaintiff's Counsel: Fenwick & West LLP
• Case Identification: 2:23-cv-04027, D.N.J., 07/27/2023
• Venue Allegations: Plaintiff alleges venue is proper because Defendant conducts business in New Jersey, derives revenue from the state, and has previously availed itself of the jurisdiction by litigating other patent disputes in the district.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the diabetes drug Victoza® constitutes an act of infringement of two patents covering the drug's formulation and its injection device.
• Technical Context: The dispute involves pharmaceutical formulations for GLP-1 agonists, a class of drugs used to treat type 2 diabetes, and the mechanical design of pen-style injection devices used for self-administration.
• Key Procedural History: The action was triggered by Defendant's submission of ANDA No. 215421 to the U.S. Food and Drug Administration. On June 12, 2023, Defendant sent a Notice Letter to Plaintiff including a Paragraph IV certification, asserting that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by its proposed generic product. This complaint was filed within the 45-day statutory window following receipt of that notice.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833 - Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and For Use in Injection Devices

The Invention Explained

• Problem Addressed: The patent's background section identifies a problem with using mannitol, a common agent for ensuring proper tonicity in injectable drug formulations. Mannitol was found to crystallize during production, leading to deposits on filling equipment, and could also cause clogging of the fine needles used in injection devices '833 Patent, col. 1:30-49
• The Patented Solution: The invention replaces mannitol with propylene glycol as the isotonicity agent in peptide formulations '833 Patent, abstract This solution is described as reducing deposits on production equipment and minimizing the clogging of injection needles, as illustrated by comparative photographs in the patent '833 Patent, col. 1:50-57 '833 Patent, FIG. 7
• Technical Importance: This solution enhances the efficiency and yield of pharmaceutical manufacturing and improves the reliability and safety of self-administered injection pens for patients '833 Patent, col. 1:35-49 '833 Patent, col. 2:39-48

Key Claims at a Glance

• The complaint asserts infringement of claims 1-31 ('833 Patent, Compl. ¶22).
• Independent claim 1 includes the following essential elements:
  • A pharmaceutical formulation comprising at least one GLP-1 agonist;
  • a disodium phosphate dihydrate buffer;
  • propylene glycol;
  • wherein said propylene glycol is present in said formulation in a final concentration of from about 1 mg/ml to about 100 mg/ml; and
  • wherein said formulation has a pH of from about 7.0 to about 10.0.

U.S. Patent No. 9,265,893 - Injection Button

The Invention Explained

• Problem Addressed: In pen-style injection devices, the act of depressing the push button to deliver a dose often involves relative rotation between the button (held stationary by the user's finger) and an internal driving mechanism. This rotation creates friction, which increases the force a user must apply to perform the injection '893 Patent, col. 1:46-54
• The Patented Solution: The invention creates a "pivot bearing" between the push button and the driving part. This design minimizes the surface area of interaction and the radius of the resulting friction, thereby reducing the overall force required to activate the device and inject the drug '893 Patent, abstract '893 Patent, col. 1:55-59 '893 Patent, FIG. 1
• Technical Importance: By minimizing the required injection force, the invention makes the device easier and more comfortable to operate, which is particularly beneficial for patients with diminished hand strength '893 Patent, col. 1:43-45

Key Claims at a Glance

• The complaint asserts infringement of claims 1-6 ('893 Patent, Compl. ¶28).
• Independent claim 1 includes the following essential elements:
  • A push button connection for an injection device;
  • comprising a push button mountable on a driving part being rotatable relatively to the push button;
  • the push button comprises a bore with a bottom surface, which surrounds a protrusion on the driving part;
  • the protrusion has a top surface;
  • a pivot bearing is formed between the bottom surface [of the bore] and the top surface [of the protrusion];
  • wherein when a user presses the push button, the force is directed toward the driving part and the driving part rotates relative to the push button.

III. The Accused Instrumentality

Product Identification

• Defendant's proposed generic liraglutide injection solution, 18 mg/3 ml (6 mg/ml), for which it submitted ANDA No. 215421 to the FDA Compl. ¶10 Compl. ¶17

Functionality and Market Context

• The complaint alleges that the Defendant's product is a generic version of Plaintiff's Victoza® product Compl. ¶17 As an ANDA product, it is alleged to be bioequivalent to Victoza® and rely on the Victoza® New Drug Application (NDA) for its approval Compl. ¶18 The infringement allegations are premised on the Defendant's product having the same formulation and being delivered via an injection device with the same functional characteristics as those covered by the patents-in-suit Compl. ¶15

IV. Analysis of Infringement Allegations

The complaint does not contain a detailed infringement analysis or claim chart. The infringement theory is based on the statutory act of filing an ANDA for a product that, if approved, would infringe the patents-in-suit Compl. ¶21 Compl. ¶27 The following charts summarize the infringement allegations, which are inferred from the complaint's assertion that Defendant's generic product is a copy of Plaintiff's patented Victoza® product Compl. ¶15 Compl. ¶17

U.S. Patent No. 8,114,833 Infringement Allegations

U.S. Patent No. 9,265,893 Infringement Allegations

Identified Points of Contention:

• Scope Questions: For the '833 Patent, a potential issue is the scope of the term "about" as it applies to the claimed concentration and pH ranges. For the '893 Patent, a key question may be whether the term "pivot bearing" can be construed to cover alternative low-friction interfaces that Defendant might employ in a design-around attempt.
• Technical Questions: The complaint does not provide any test data or reverse-engineering results for Defendant's product. A primary technical question will be whether discovery confirms that the proposed generic formulation and device literally meet every limitation of the asserted claims.

V. Key Claim Terms for Construction

• The Term: "about" ('833 Patent, Claim 1)
• Context and Importance: This term modifies the numerical ranges for both propylene glycol concentration and pH. The breadth of its definition will be critical to the infringement analysis, as a formulation falling slightly outside the explicit numerical ranges could still infringe if "about" is construed broadly, but would not if construed narrowly.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent specification uses the term "about" consistently when discussing concentration and pH ranges, suggesting an intent to claim more than the precise numbers stated '833 Patent, col. 10:17-36
  • Evidence for a Narrower Interpretation: The patent provides specific working examples with precise values (e.g., 14.0 mg/ml propylene glycol, pH 8.15) which a defendant may argue cabin the reasonable scope of "about" to values very close to those explicitly tested and disclosed '833 Patent, col. 19:57-62
• The Term: "pivot bearing" ('893 Patent, Claim 1)
• Context and Importance: This term defines the core structural feature of the claimed invention for reducing injection force. Infringement will depend on whether the interface between the push button and driving part in Defendant's device creates a structure meeting the definition of a "pivot bearing."
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification describes the function of the pivot bearing as minimizing the surface area of interaction and the radius of friction, which could support a construction that covers any structure achieving this functional goal '893 Patent, col. 1:55-59
  • Evidence for a Narrower Interpretation: The specification describes a specific embodiment where the pivot bearing is formed by a "raised pointer" on the bottom surface of the bore '893 Patent, col. 3:65-67 A defendant may argue that the term should be limited to this disclosed structure or structurally equivalent variations.

VI. Other Allegations

• Indirect Infringement: This action is brought under 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA as a statutory act of infringement for jurisdictional purposes. The complaint does not plead separate counts for induced or contributory infringement.
• Willful Infringement: The complaint alleges that Defendant "was aware" of both the '833 patent and the '893 patent when it submitted its ANDA Compl. ¶25 Compl. ¶31 This alleged pre-suit knowledge forms the basis for Plaintiff's request for a finding of exceptional case status and an award of attorneys' fees Compl. Prayer for Relief ¶F

VII. Analyst's Conclusion: Key Questions for the Case

1. Chemical and Mechanical Identity: A primary issue will be factual and evidentiary: will discovery confirm that Defendant's proposed generic formulation and injection device are exact or legally equivalent copies that fall within the scope of the asserted claims? Any deviation in the generic product's chemical composition, pH, or mechanical design will become a central point of the non-infringement dispute.
2. Scope of "About": The construction of the term "about" in the '833 patent's formulation claims will be a key legal battleground. Whether the term allows for a meaningful degree of variation or is limited to minor instrument error could determine the outcome of the infringement analysis for the formulation patent.
3. Validity Challenge: A core of the case will be the Defendant's invalidity contentions, as asserted in its Paragraph IV certification Compl. ¶19 The ultimate outcome will likely depend not just on infringement, but on whether the Defendant can prove by clear and convincing evidence that the asserted claims were unpatentable in view of the prior art at the time of invention.